It’s still a bull thesis, just subverted: Molecular Templates Inc (MTEM)

At the time of writing, Molecular Templates Inc [MTEM] stock is trading at $2.24, down -5.08%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MTEM shares have gain 24.44% over the last week, with a monthly amount drifted -41.67%, and not seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

On 28, March 2024, Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement. In a post published today on Yahoo Finance, Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announced today it has entered into a definitive amended and restated securities purchase agreement with certain healthcare investors that will provide $9.5 million in gross proceeds to MTEM through the closing of the second tranche of its previously announced July 2023 private placement and purchase agreement on amended terms. The financing is being led by existing investor BVF Partners L.P. and includes existing investors BB Biotech AG and Santé, and other leading institutional investors.

From an analyst’s perspective:

Molecular Templates Inc [NASDAQ: MTEM] stock has seen the most recent analyst activity on April 21, 2021, when BofA Securities initiated its Buy rating and assigned the stock a price target of $12. Previously, UBS started tracking the stock with Neutral rating on February 01, 2021, and set its price target to $13. On September 08, 2020, Jefferies initiated with a Buy rating and assigned a price target of $21 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $19 on March 25, 2020. Barclays initiated its recommendation with a Overweight and recommended $22 as its price target on February 27, 2020. UBS started tracking with a Buy rating for this stock on April 29, 2019, and assigned it a price target of $12. In a note dated December 11, 2018, Oppenheimer initiated an Outperform rating and provided a target price of $15 on this stock.

For the past year, the stock price of Molecular Templates Inc fluctuated between $1.68 and $9.45. Molecular Templates Inc [NASDAQ: MTEM] shares were valued at $2.24 at the most recent close of the market.

Analyzing the MTEM fundamentals

According to Molecular Templates Inc [NASDAQ:MTEM], the company’s sales were 52.90M for trailing twelve months, which represents an 60.28% jump. Gross Profit Margin for this corporation currently stands at 0.27% with Operating Profit Margin at -0.32%, Pretax Profit Margin comes in at -0.36%, and Net Profit Margin reading is -0.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is 4.28 and Total Capital is -0.7. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.88.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.97 points at the first support level, and at 1.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.65, and for the 2nd resistance point, it is at 3.05.

Molecular Templates Inc [MTEM] reported earnings per share of -$0.82 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.39/share, meaning a difference of $0.57 and a surprise factor of 41.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$2.85 per share as compared to estimates of -$5.17 per share, a difference of $2.32 representing a surprise of 44.90%.

Ratios To Look Out For

It is important to note that Molecular Templates Inc [NASDAQ:MTEM] has a current ratio of 1.06. In addition, the Quick Ratio stands at 1.06 and the Cash Ratio stands at 0.73. Considering the valuation of this stock, the price to sales ratio is 0.23, the price to book ratio is 1.77.